Global biotech investors are stepping up activity in Singapore, as the city-state leverages its talent base, R&D strengths and EDB-backed incentives to anchor Asia-Pacific life sciences growth.
Across the Asia-Pacific, life‑sciences firms are forging strategic licensing partnerships to fast‑track innovation, seize surging regional demand, and navigate complex IP landscapes-moves that are rewriting growth trajectories and reshaping competitive dynamics
Asia-Pacific’s medtech sector is breaking into a bold new era – Bain & Company maps how regional innovators are scaling onto the global stage, disrupting rivals and drawing record investment
Global science innovation is rapidly shifting to Asia as investment, talent, and R&D infrastructure surge, challenging Western dominance and reshaping pharmaceutical competition worldwide.
Asia Society’s new report probes the changing landscape of U.S.-China relations in the life sciences, where competition and collaboration increasingly intertwine. It highlights policy flashpoints, deep research linkages, and the wider implications for global health security
Asia’s life science ecosystems have surged in biomedical innovation over the past decade, driven by increased R&D investment, cutting-edge technology, and growing collaboration between industry and academia, reports Nature.
PR Newswire reports that the 2023 Asia Health and Life Sciences Innovation and Cooperation Summit showcased breakthrough technologies and bold cross-border partnerships, offering fresh insights into the future of healthcare across the region